SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance

SI-BONE posts strong Q3 revenue growth with narrowing losses and reaffirms 2026 guidance.

What the company is saying

SI-BONE, Inc. emphasizes robust third-quarter growth, citing a 14.5% year-over-year increase in worldwide revenue to $55.7 million and a 13.9% rise in U.S. revenue to $52.8 million. CEO Laura Francis frames the narrative around rising demand, a record number of active physicians, and early uptake of new technologies such as iFuse Granite Onyx, which expands the estimated total addressable market to $5 billion. The company highlights favorable DRG changes and strong procedure volume growth, particularly a 19.5% increase in the U.S., though it acknowledges this was partially offset by lower average selling prices due to procedure mix and increased demand for the INTRA platform in office-based and ASC settings. International revenue grew 27.0% to $2.9 million, attributed to adoption of iFuse TORQ and iFuse TORQ TNT. SI-BONE reaffirms its 2026 revenue and gross margin guidance, lowering operating expense growth expectations to 10.5% and projecting positive adjusted EBITDA for the year. The tone is confident, focusing on operational momentum, new product launches, and a foundation for accelerated growth into 2027.

What the data suggests

The disclosed figures show SI-BONE’s financial trajectory is improving. Q3 2026 worldwide revenue reached $55.7 million, up 14.5% from $48.7 million in Q3 2025, with U.S. revenue at $52.8 million and international revenue at $2.9 million. Gross profit increased 13.7% to $44.2 million, while gross margin remained high at 79.3%, slightly down from 79.8% due to procedure and site of care mix. Operating expenses rose 9.7% to $48.5 million, mainly from higher sales commissions, marketing for new launches, and R&D investment. Operating loss narrowed by 19.2% to $4.4 million, and net loss improved by 20.7% to $3.6 million ($0.08 per diluted share). Adjusted EBITDA turned positive at $3.0 million, up from $2.3 million. Cash and equivalents were stable at $146.3 million, with net cash generated in the quarter at $0.4 million. The company reaffirmed 2026 revenue guidance of $231–$233 million (~15–16% growth), gross margin near 79.0%, and expects positive adjusted EBITDA. The evidence supports the narrative of operational improvement and controlled expense growth, though qualitative claims about procedure volume and product adoption lack granular breakdowns.

Analysis

The announcement presents a positive tone, highlighting double-digit revenue growth, improved gross profit, narrowing losses, and positive adjusted EBITDA. These improvements are supported by detailed, realised financial data for the quarter, including revenue, gross profit, operating loss, net loss, and cash flow. Forward-looking statements are limited to reaffirmed guidance for full-year 2026 revenue, gross margin, and adjusted EBITDA, all of which are near-term (within the next 12 months). There is no evidence of exaggerated claims or narrative inflation; the language is proportionate to the disclosed results, and there are no unsupported projections of long-term transformation or outsized future benefits. The only minor gap is the lack of numerical detail for some qualitative drivers (procedure volume, product adoption), but this does not materially inflate the signal. No large capital outlay is disclosed without immediate earnings impact.

Risk flags

• ●Profitability remains a risk, as SI-BONE continues to report net and operating losses despite narrowing deficits. Sustained losses could pressure cash reserves if revenue growth slows or expenses rise unexpectedly.
• ●Gross margin, while high at 79.3%, showed a slight decline from 79.8% due to changes in procedure and site of care mix. Further shifts in procedure mix or pricing pressure could erode margins.
• ●The company’s growth narrative relies on continued adoption of new products and technologies, such as iFuse Granite Onyx and the INTRA platform. If uptake slows or competitive dynamics shift, revenue growth could decelerate.
• ●Operating expense growth, although reduced in guidance to 10.5%, is still significant and driven by sales commissions, marketing, and R&D. If these investments do not translate into further revenue acceleration, operating leverage may not materialize as expected.

Bottom line

SI-BONE delivered double-digit revenue growth and improved profitability metrics in Q3 2026, with net loss and operating loss both narrowing and adjusted EBITDA turning positive. The company’s reaffirmed 2026 guidance for revenue, gross margin, and adjusted EBITDA signals management confidence in near-term performance, supported by strong procedure volume and new product uptake. However, the business is not yet profitable on a net basis, and future margin or expense pressures could challenge the path to sustained earnings. The company’s cash position remains solid, but ongoing investments in sales, marketing, and R&D must yield further revenue gains to justify expense growth. Investors should focus on the company’s ability to convert procedure and product adoption into lasting profitability, with the most important takeaway being the demonstrated operational improvement but ongoing need for vigilance on expense control and margin sustainability.

Announcement summary

(NASDAQ:SIBN) SI-BONE, Inc. reported financial results for the quarter ended September 30, 2026. Worldwide revenue for the third quarter 2026 was $55.7 million, representing a 14.5% increase from $48.7 million in the third quarter 2025. U.S. revenue for the third quarter 2026 was $52.8 million, up 13.9% from $46.4 million in the prior year period, driven by approximately 19.5% growth in procedure volume, partially offset by lower average selling price due to procedure mix and increased demand for the INTRA platform in office-based and ASC sites of care. International revenue for the third quarter 2026 was $2.9 million, a 27.0% increase from $2.3 million in the third quarter 2025, reflecting increased adoption of iFuse TORQ and iFuse TORQ TNT. Gross profit for the third quarter 2026 was $44.2 million, up 13.7% from $38.8 million in the prior year, with a gross margin of 79.3% compared to 79.8% in the third quarter 2025, impacted by procedure and site of care mix. Operating expenses rose 9.7% to $48.5 million in the third quarter 2026 from $44.2 million in the prior year, primarily due to higher sales commissions, marketing for new product launches, and continued R&D investment. Operating loss improved by 19.2% to $4.4 million in the third quarter 2026 from $5.4 million in the prior year. Net loss improved by 20.7% to $3.6 million, or $0.08 per diluted share, compared to $4.6 million, or $0.11 per diluted share, in the third quarter 2025. Adjusted EBITDA was $3.0 million in the third quarter 2026, up from $2.3 million in the prior year. Cash and equivalents as of September 30, 2026 were $146.3 million, compared to $145.9 million as of June 30, 2026. Net cash generated in the third quarter 2026 was $0.4 million, compared to $0.2 million in the prior year period. SI-BONE reaffirmed its 2026 worldwide revenue and gross margin guidance, with revenue expected to be between $231 million and $233 million, representing approximately 15-16% growth, and gross margin around 79.0%. The company reduced its operating expense growth expectation for 2026 to 10.5% at the revenue midpoint, down from the prior 12.0%. Adjusted EBITDA is expected to be positive for the fiscal year. As of September 30, 2026, total assets were $256.8 million and total liabilities were $72.1 million. Since 2009, SI-BONE has supported physicians in over 160,000 procedures. The company’s technology platform includes iFuse Bedrock Granite, iFuse TORQ, iFuse TORQ TNT, iFuse Granite Onyx, and iFuse INTRA. Laura Francis is the Chief Executive Officer of SI-BONE. The company hosted a conference call to discuss these results on November 2, 2026 at 4:30 P.M. Eastern Time.

Disagree with this article?